Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell Therapy

Adam Johnson(Sana Biotechnology (United States)), Terry J. Fry(University of Colorado Anschutz Medical Campus), Andrew McAlister(University of Auckland), Neal Van Hoeven(Sana Biotechnology (United States)), Hallee Wright(Sana Biotechnology (United States)), Trevor J. McGill(Brigham and Women's Hospital), Sundeep Chandra(Sana Biotechnology (United States)), Sonja Schrepfer(Cedars-Sinai Medical Center), Kerrie Enger(Sana Biotechnology (United States)), Chi Young(Sana Biotechnology (United States)), Ouwen Liang(Sana Biotechnology (United States)), Jenny Migliaccio(Sana Biotechnology (United States)), Boris Gorovits(Pfizer (United States)), Prasanna Kumar(St.John's Medical College Hospital), Brian Granger(Sana Biotechnology (United States)), Shannon Joyce(Sana Biotechnology (United States)), Tori Duback(Sana Biotechnology (United States)), Chris Baldeviano(Sana Biotechnology (United States)), Xiaomeng Hu(Huzhou University), Anna Liang(University of Toronto), Sam Crocker(Sana Biotechnology (United States)), Carrie Rocca(Sana Biotechnology (United States)), Vasily V. Vagin(Sana Biotechnology (United States)), Jeremy M. Kinder(Sana Biotechnology (United States))
Blood
November 2, 2023
Cited by 4


Related Papers